New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
10:04 EDTASH, COG, GMAN, MWV, MGLN, KRA, SWN, ZIOP, TWOOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Ashland (ASH) downgraded to Neutral from Buy at Longbow... Cabot Oil & Gas (COG) downgraded to Hold from Buy at Stifel... Gordmans Stores (GMAN) downgraded to Neutral from Overweight at Piper Jaffray... Kraton Performance (KRA) downgraded to Perform from Outperform at Oppenheimer... Magellan Health (MGLN) downgraded to Market Perform from Outperform at Raymond James... MeadWestvaco (MWV) downgraded to Neutral from Buy at UBS... Southwestern Energy (SWN) downgraded to Hold from Buy at Stifel... Ziopharm (ZIOP) downgraded to Underperform from Market Perform at BMO Capital... Two Harbors (TWO) downgraded to Neutral from Buy at Compass Point... Cabot Oil & Gas (COG) downgraded to Hold from Buy at Stifel... Southwestern Energy (SWN) downgraded at Stifel.
News For ASH;COG;GMAN;MWV;MGLN;KRA;SWN;ZIOP;TWO From The Last 14 Days
Check below for free stories on ASH;COG;GMAN;MWV;MGLN;KRA;SWN;ZIOP;TWO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 25, 2014
10:02 EDTCOGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:44 EDTMGLNMagellan Health sees FY14 adjusted EPS $2.67-$3.32, consensus $2.40
Sees FY14 segment profit $238M-$258M; Sees FY14 cash flow from operations $204M-$226M
06:43 EDTMGLNMagellan Health reports Q2 adjusted EPS 39c, consensus 57c
Subscribe for More Information
06:07 EDTCOGCabot Oil & Gas downgraded to Neutral from Outperform at RW Baird
RW Baird downgraded Cabot Oil & Gas to Neutral following the company's Q2 results saying realizations is likely to limit near-term upside. The firm has a $43 price target for shares.
July 24, 2014
08:12 EDTASHAshland reinstated as a Conviction Buy from Not Rated at Goldman
Subscribe for More Information
07:44 EDTCOGCabot Oil & Gas reports Q2 Marcellus Shale averaged 1,258 Mmcf per day
Subscribe for More Information
07:43 EDTCOGCabot Oil & Gas reports Q2 production of 127.6 Bcfe
Reports Q2 liquids production of 961,000 barrels, an increase of 26% over last year's comparable quarter as reported; Reports Q2 crude oil and condensate production of 869,000 barrels, an increase of 25% over last year's comparable quarter as reported; Natural gas price realizations, including the effect of hedges, were $3.47 per thousand cubic feet in Q2. the impact of hedges, natural gas price realizations for the quarter were $3.78 per Mcf. Total per unit costs decreased to $2.59 per Mcfe in the second quarter of 2014, down 16 percent from $3.10 per Mcfe in the second quarter of 2013.
07:42 EDTCOGCabot Oil & Gas reports Q2 adjusted EPS 28c, consensus 25c
Subscribe for More Information
July 23, 2014
08:15 EDTCOGCabot Oil & Gas price target lowered to $43 from $52 at RW Baird
Subscribe for More Information
July 22, 2014
07:15 EDTZIOPZiopharm announces expansion of oncology programs with Intrexon
Ziopharm (ZIOP) announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon (XON) to include chimeric antigen receptor T-cell, or CAR-T, therapy. Additionally the company has provided an update on its development efforts with the proprietary RheoSwitch Therapeutic System, or RTS, platform, an inducible regulator for expression of therapeutic molecules through administration of an oral activator ligand, as well as its clinical program with Ad-RTS-IL-12, a novel DNA-based therapeutic candidate for the controlled expression of IL-12. CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints, yet current approaches feature challenges associated with toxicity, off-target effects, and uneconomical manufacturing. Intrexon possesses the integrated technology platforms, molecular engineering, systems biology, and cell engineering capabilities required to overcome these challenges and fully realize the potential of CAR]T cell therapies. Most significantly, utilization of the RTS platform will facilitate exquisite regulation of one or more bioeffectors in CAR-T cells enabling physicians to control systemic effects of cell therapies with an appropriate dosing regimen of the oral activator ligand, and eventually bring about improved safety and efficacy of these and related therapeutic strategies. Further preclinical work is underway in this promising area of study, and ZIOPHARM and Intrexon expect to provide a progress update in the second half of 2014.
July 17, 2014
10:00 EDTCOGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:08 EDTCOGCabot Oil & Gas initiated with a Market Perform at FBR Capital
Subscribe for More Information
July 16, 2014
17:36 EDTCOGCabot Oil & Gas initiated with a Hold at Canaccord
Subscribe for More Information
15:21 EDTMWVStarboard's Smith says had constructive talks with MeadWestvaco, Bloomberg says
Smith says company's chemical unit worth $3.5B and reiterated that MeadWestvaco shares may have upside potential over $59 per share, Bloomberg added.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use